For ELN and SCE vendors
Electronic lab notebooks and scientific computing environments hold the data. TIDE-GxP supplies the gene editing analysis, with the validation evidence regulated customers require.
Start a partnership conversationBoth routes deliver the same analysis and the same validation evidence. The difference is whose product the customer sees.
Embed TIDE analysis inside your platform
Suits vendors whose customers already store sequencing data and experiment records in their platform.
Offer TIDE-GxP under your own product
Suits vendors who want a regulated-grade analysis module without building and validating one in-house.
TIDE is used daily by researchers worldwide and appears in thousands of publications, including work behind an FDA-approved cell therapy. Your customers recognise it.
TIDE-GxP is delivered with validation documentation, IQ/OQ/PQ protocols and 21 CFR Part 11 audit trails, which is what pharmaceutical customers ask of any analysis in their record system.
Developing editing analysis is one project. Validating it and maintaining that validation is a permanent one. Partnering removes both from your roadmap.
We map your customer base, use cases and the analysis gap you want to close.
We review data formats, workflow fit and whether integration or licensing serves you better.
We agree licensing, support obligations and territory in a written partnership agreement.
We support launch with documentation, training material and a defined support path for your customers.
Tell us about your platform and your customers, and we will propose the route that fits best.